Health-System Specialty Pharmacy Outcomes Research Consortium

Completed and Ongoing Research Projects (As of Spring 2022):

Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies (https://doi.org/10.1093/ajhp/zxab342)

• This large, multisite retrospective cohort study was the first to demonstrate adherence rates across several HSSPs and provided novel insights into rates and reasons for appropriate gaps in therapy
• Across 20 participating sites, the median adherence rate (measured by proportion of days covered [PDC]) was 0.94 using data from 29,994 prescriptions and 3,530 patients.

Management of Patients with Multiple Sclerosis within Health-System Specialty Pharmacies: Actions and Outcomes

• This multisite prospective cohort study will be the first to report adherence and outcomes in patients with MS across multiple health-system specialty pharmacies. Additionally, it will provide needed insight into health-system specialty pharmacy management of patients with MS.
• Results from this study will be presented at national conferences throughout 2022.

Clinical Services Provided by Health-Systems Specialty Pharmacies: A Survey of Current Practice

• The objective of this multi-phased survey is to aggregate data to demonstrate the benefits of a health-system specialty pharmacy (HSSP) by demonstrating the clinical services provided by HSSPs.
• A review of literature describing the role and outcomes of HSSPs has been submitted for publication
• The Consortium partnered with ASHP to disseminate a survey to HSSPs assessing currently provided clinical services; results pending

Safety Screening in Patients Initiating Biologic Specialty Medications

• This prospective cohort study will evaluate the role HSSPs play in patients safely initiating self-administered biologic therapies.
• Study design and execution are currently in process.

Safety Screening in Patients Initiating Biologic Specialty Medications

• This prospective cohort study will evaluate the role HSSPs play in patients safely initiating self-administered biologic therapies.
• Study design and execution are currently in process.

Use of Deutetrabenazine Above Food and Drug Administration Maximum Recommended Dose

• This retrospective study will assess the safety and effectiveness of deutetrabenazine doses greater than the currently DFA-approved 28mg per day.
• Study design and execution are currently in process.

Networking and Educational Events:

Journal Club and Hot Topic Roundtables

The Consortium hosts a monthly event that alternates between a journal club, wherein authors present results from an applicable study, and a hot topic roundtable on a specialty pharmacy topic of interest. Both events include a brief presentation followed by discussion between presenters and attendees.